An investigation for investors in NASDAQ:INSM shares over potential securities laws violations by Insmed and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of Insmed Incorporated (NASDAQ:INSM), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Insmed Incorporated (NASDAQ:INSM) concerning whether a series of statements by Insmed regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On June 8, 2016, post-market, Insmed Incorporated announced that it had withdrawn a European marketing application submitted to the European Medicines Agency for its lung disease drug Arikayce. Insmed Incorporated stated that the marketing application was based on data from a mid-stage clinical study that didn’t support enough evidence for an approval from the European Medicines Agency. Insmed Incorporated stated that the Company will resubmit the application when data is available from a later study.
Shares of Insmed Incorporated (NASDAQ:INSM) declined to $9.95 per share on June 9, 2016.
On June 27, 2016, NASDAQ:INSM shares closed at $9.05 per share.
Those who purchased NASDAQ:INSM shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego